New Market Launch: TIEFENBACHER PHARMACEUTICALS successfully launches generic version of the anticoagulant medicine Apixaban in Canada

We at TIEFEENBACHER PHARMACEUTICALS are driven by enabling people around the world a better access to more affordable high-quality medicines. That´s why we are happy to share that we have successfully prepared the launch of the generic version of Apixaban for an early market entry in Canada.
Apixaban is an oral anticoagulant (blood thinner) indicated for the prevention of venous thromboembolism (VTE) in adult patients who have undergone elective hip or knee replacement surgery, for the prevention of stroke and systemic embolism in patients with atrial fibrillation, and for the treatment of deep vein thrombosis (DVT) and pulmonary embolism (PE) and the prevention of their recurrence. 2,5 mg and 5 mg tablets have been developed in TIEFENBACHER GROUP’s own laboratories in India and will be marketed in Canada by our cooperation partner, one of the biggest generic pharmaceuticals in the world.
A generic launch in further international markets will follow. With this early market entry TIEFENBACHER PHARMACEUTICALS achieves nameable savings for the international health care systems and enables millions of patients a better affordable access to a life-improving treatment.

TIEFENBACHER PHARMACEUTICALS, a part of Tiefenbacher Group, develops and commercializes genericvalue added, and innovative pharmaceuticals as well as medical devices and e-health solutions worldwide. We provide over 180+ pharmaceutical products across various therapeutic categories in 10+ dosage forms. With our in-house product development and manufacturing, we can address specific therapeutic needs in unique formulations of prescription drugs (Rx) and over-the-counter (OTC) medicines for global markets (including highly potent drugs).
For more information about our finished dosage forms and healthcare solutions, please contact Tiefenbacher Pharmaceuticals: or visit us on: